Neuromuscular DiseasesNeuromuscular DiseasesНервно-мышечные болезни2222-87212413-0443Publishing House ABV Press1010.17650/2222-8721-2014-0-1-40-47ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯThe specific features of Guillain–Barré syndrome in Russia: Analysis of 186 casesОсобенности течения СГБ в России: анализ 186 случаевSuponevaN. A.СупоневаН. А.Russian Federationnasu2709@mail.ruMochalovaE. G.МочаловаЕ. Г.Russian FederationGrishinaD. A.ГришинаД. А.Russian FederationPiradovM. A.ПирадовМ. А.Russian FederationResearch Center of Neurology, Russian Academy of Medical Sciences, MoscowФГБУ «Научный центр неврологии» РАМН, МоскваMoscow State University named after M.V. LomonosovМГУ им. М.В. Ломоносова190420144137461902201519022015Copyright ©; 2014, Suponeva N.A., Mochalova E.G., Grishina D.A., Piradov M.A.Copyright ©; 2014, Супонева Н.А., Мочалова Е.Г., Гришина Д.А., Пирадов М.А.2014Suponeva N.A., Mochalova E.G., Grishina D.A., Piradov M.A.Супонева Н.А., Мочалова Е.Г., Гришина Д.А., Пирадов М.А.https://creativecommons.org/licenses/by/4.0https://nmb.abvpress.ru/jour/article/view/10Guillain–Barré syndromeacute inflammatory demyelinating polyneuropathyacute motor axonal neuropathyacute sensorimotor axonal neuropathyaxonal neuropathytriggerprecipitating factorseveritytherapeutic effectivenessrecoveryсиндром Гийена–Барреострая воспалительная демиелинизирующая полинейропатияострая моторная аксональная невропатияострая моторно-сенсорная аксональная невропатияаксональная невропатиятриггерпровоцирующий фактортяжестьэффективность терапии,[1. Пирадов М.А. Синдром Гийена–Барре. М.: Интермедика, 2003. 240 с.Пирадов М.А. Синдром Гийена–Барре. М.: Интермедика, 2003. 240 с.][2. Супонева Н.А., Пирадов М.А., Никитин С.С., Алферова В.П. Острый гипокалиемический паралич вследствие передозировки препарата, содержащего корень солодки. Анн клин и экспер неврол 2008;1(2):47–51.Супонева Н.А., Пирадов М.А., Никитин С.С., Алферова В.П. Острый гипокалиемический паралич вследствие передозировки препарата, содержащего корень солодки. Анн клин и экспер неврол 2008;1(2):47–51.][3. Pithadia А.B., Kakadia N. Guillain–Barré syndrome (GBS). Pharmacological Reports 2010;62:220–32.Pithadia А.B., Kakadia N. Guillain–Barré syndrome (GBS). Pharmacological Reports 2010;62:220–32.][4. McGrogan A., Madle G.C., Seaman H.E., de Vries C.S. The epidemiology of Guillain– Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009;32(2):150–63.McGrogan A., Madle G.C., Seaman H.E., de Vries C.S. The epidemiology of Guillain– Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009;32(2):150–63.][5. Sejvar J.J., Baughman A.L., Wise M. Morgan O.W. Population incidence of Guillain–Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36(2):123–33.Sejvar J.J., Baughman A.L., Wise M. Morgan O.W. Population incidence of Guillain–Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36(2):123–33.][6. van Doorn P.A., Ruts L., Jacobs B.C. Clinical features, pathogenesis, and treatment of Guillain–Barré syndrome. Lancet Neurol 2008;7(10):939–50.van Doorn P.A., Ruts L., Jacobs B.C. Clinical features, pathogenesis, and treatment of Guillain–Barré syndrome. Lancet Neurol 2008;7(10):939–50.][7. Супонева Н.А., Пирадов М.А., Гнедовская Е.В. и др. Синдром Гийена–Барре: анализ оказания диагностической и лечебной помощи пациентам. Журн неврол и психиатр 2013;4:45–9.Супонева Н.А., Пирадов М.А., Гнедовская Е.В. и др. Синдром Гийена–Барре: анализ оказания диагностической и лечебной помощи пациентам. Журн неврол и психиатр 2013;4:45–9.][8. Hughes R.A., Cornblath D.R. Gullain–Barré syndrome. Lancet 2005;366:1653–66.Hughes R.A., Cornblath D.R. Gullain–Barré syndrome. Lancet 2005;366:1653–66.][9. Супонева Н.А., Пирадов М.А.,Никитин С.С. и др. Патогенетическая и прогностическая роль аутоантител к гликозидам периферических нервов при синдроме Гийена–Барре. Анн неврол 2013;7(1):4–11.Супонева Н.А., Пирадов М.А.,Никитин С.С. и др. Патогенетическая и прогностическая роль аутоантител к гликозидам периферических нервов при синдроме Гийена–Барре. Анн неврол 2013;7(1):4–11.][10. Ho T.W., Mishu B., Li C.Y. Gullain–Barré syndrome in Nothern China. Relaitionship to Campylobacter Jejuni infection and antiglycolipid antibodies. Brain 1995;118:597–605.Ho T.W., Mishu B., Li C.Y. Gullain–Barré syndrome in Nothern China. Relaitionship to Campylobacter Jejuni infection and antiglycolipid antibodies. Brain 1995;118:597–605.][11. Yuki N. Carbohydrate mimicry: a new paradigm of autoimmune disease. Curr Opin Immunol 2005;17:577–82.Yuki N. Carbohydrate mimicry: a new paradigm of autoimmune disease. Curr Opin Immunol 2005;17:577–82.][12. Lehmann H.C., Hartung H.P., Kieseier B.C. Hughes R.A. Guillain–Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010;10(9):643–51.Lehmann H.C., Hartung H.P., Kieseier B.C. Hughes R.A. Guillain–Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010;10(9):643–51.][13. Yuki N., Hartung H.-P. Guillain–Barré syndrome. N Engl J Med 2012;366:2294– 304.Yuki N., Hartung H.-P. Guillain–Barré syndrome. N Engl J Med 2012;366:2294– 304.][14. Baig F., Knopp M., Rajabally Y.A. Diagnosis, epidemiology and treatment of inflammatory neuropathies. Br J Hosp Med (Lond) 2012;3(7):80–5.Baig F., Knopp M., Rajabally Y.A. Diagnosis, epidemiology and treatment of inflammatory neuropathies. Br J Hosp Med (Lond) 2012;3(7):80–5.][15. Feasby T.E., Gilbert J.J., Brown W.F. et al. An acute axonal form of Guillain– Barré polyneuropathy. Brain 1986;109 (Pt 6):1115–26.Feasby T.E., Gilbert J.J., Brown W.F. et al. An acute axonal form of Guillain– Barré polyneuropathy. Brain 1986;109 (Pt 6):1115–26.][16. Wee A.S., Abernathy S.D. The sural sensory nerve is usually spared in Guillain– Barré syndrome. J Miss State Med Assoc 2003;44:251–55.Wee A.S., Abernathy S.D. The sural sensory nerve is usually spared in Guillain– Barré syndrome. J Miss State Med Assoc 2003;44:251–55.][17. Ye Y., Wang K., Deng F., Xing Y. Electrophysiological subtypes and prognosis of Guillain–Barré syndrome in Northeastern China. Muscle & Nerve 2013;47(1):68–71.Ye Y., Wang K., Deng F., Xing Y. Electrophysiological subtypes and prognosis of Guillain–Barré syndrome in Northeastern China. Muscle & Nerve 2013;47(1):68–71.][18. Hadden R.D., Cornblath D.R., Hughes R.A. et al. Electrophysiological classification of Guillain–Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group. Ann Neurol 1998;44(5):780–8.Hadden R.D., Cornblath D.R., Hughes R.A. et al. Electrophysiological classification of Guillain–Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group. Ann Neurol 1998;44(5):780–8.][19. John J. Grading of muscle power: comparison of MRC and analogue scales by physiotherapists. Medical Research Council. Int J Rehabil Res 1984;7(2):173–81.John J. Grading of muscle power: comparison of MRC and analogue scales by physiotherapists. Medical Research Council. Int J Rehabil Res 1984;7(2):173–81.][20. Mahoney F.I., Barthel D.W. Functional Evaluation: The Barthel Index. Md State Med J 1965;14:61–5.Mahoney F.I., Barthel D.W. Functional Evaluation: The Barthel Index. Md State Med J 1965;14:61–5.][21. van Nes S.I., Vanhoutte E.K., van Doorn P.A. et al. Rasch-built Overall Disability Scale (R-ODS) for immunemediated peripheral neuropathies. Neurology 2011;76(4):337–45.van Nes S.I., Vanhoutte E.K., van Doorn P.A. et al. Rasch-built Overall Disability Scale (R-ODS) for immunemediated peripheral neuropathies. Neurology 2011;76(4):337–45.][22. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиасфера, 2002.Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиасфера, 2002.][23. Rajabally Y.A., Uncini A. Outcome and its predictors in Guillain–Barre syndrome. J Neurol Neurosurg Psychiatry 2012;83(7):711–8.Rajabally Y.A., Uncini A. Outcome and its predictors in Guillain–Barre syndrome. J Neurol Neurosurg Psychiatry 2012;83(7):711–8.][24. van Konigsveld R., van Doorn P.A., Shmitz P.I. et al. Mild forms of Gullain–Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 2000;54:620–25.van Konigsveld R., van Doorn P.A., Shmitz P.I. et al. Mild forms of Gullain–Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 2000;54:620–25.][25. Koga M., Yuki N., Hirata K. Antecedent symptoms of Guillain–Barré syndrome: an important indicator for clinical and serological subgroupes. Acta Neurol Scand 2001;103:278–87.Koga M., Yuki N., Hirata K. Antecedent symptoms of Guillain–Barré syndrome: an important indicator for clinical and serological subgroupes. Acta Neurol Scand 2001;103:278–87.][26. Uncini A., Manzoli C., Notturno F. et al. Pitfalls in electrodiagnosis of Guillain-Barre syndrome subtypes. J Neurol Neurosurg Psychiatry 2010;81:1157–63.Uncini A., Manzoli C., Notturno F. et al. Pitfalls in electrodiagnosis of Guillain-Barre syndrome subtypes. J Neurol Neurosurg Psychiatry 2010;81:1157–63.][27. Hughes R.A.C., Swan A.V., Raphaёl J.S. et al. Immunotherapy for Gullain-Barré syndrome: a systematic review. Brain 2007;130:2245–57.Hughes R.A.C., Swan A.V., Raphaёl J.S. et al. Immunotherapy for Gullain-Barré syndrome: a systematic review. Brain 2007;130:2245–57.][28. Пирадов М.А., Городецкий В.М., Рябинкина Ю.В. и др. Профилактика венозных тромбоэмболических осложнений и гепарин-индуцированная тромбоцитопения у больных с острой воспалительной полиневропатией (синдром Гийена–Барре). Анн клин и экспер неврол 2012;1(6):41–6.Пирадов М.А., Городецкий В.М., Рябинкина Ю.В. и др. Профилактика венозных тромбоэмболических осложнений и гепарин-индуцированная тромбоцитопения у больных с острой воспалительной полиневропатией (синдром Гийена–Барре). Анн клин и экспер неврол 2012;1(6):41–6.][29. Hughes R.A., Pritchard J., Hadden R.D. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Gullain–Barré syndrome. Cochrane Database Syst Rev 2011;3(CD008630).Hughes R.A., Pritchard J., Hadden R.D. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Gullain–Barré syndrome. Cochrane Database Syst Rev 2011;3(CD008630).][30. Kuwabara S., Ogawara K., Misawa S. et al. Sensory nerve conduction in demyelinating and axonal Guillain–Barre syndromes. Eur Neurol 2004;51(4):196–8.Kuwabara S., Ogawara K., Misawa S. et al. Sensory nerve conduction in demyelinating and axonal Guillain–Barre syndromes. Eur Neurol 2004;51(4):196–8.][31. Ho T.W., Li C.Y., Cornblath D.R. et al. Patterns of recovery in the Guillain–Barré syndromes. Neurology 1997;48(3):695–700.Ho T.W., Li C.Y., Cornblath D.R. et al. Patterns of recovery in the Guillain–Barré syndromes. Neurology 1997;48(3):695–700.][32. Kuwabara S., Mori M., Ogawara K. et al. Indicators of rapid clinical recovery in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2001;70(4):560–2.Kuwabara S., Mori M., Ogawara K. et al. Indicators of rapid clinical recovery in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2001;70(4):560–2.][33. Uncini A.,Yuki N. Electrophysiologic and immunopathologic correlates in Guillain- Barré syndrome subtypes. Expert Rev Neurother 2009;9(6):869–84.Uncini A.,Yuki N. Electrophysiologic and immunopathologic correlates in Guillain- Barré syndrome subtypes. Expert Rev Neurother 2009;9(6):869–84.][34. Baker M.G., Kvalsvig A., Zhang J. et al. Declining Guillain–Barre syndrome after campylobacteriosis control, New Zealand, 1988–2010. Emerg Infect Dis 2012;18(2):226–33.Baker M.G., Kvalsvig A., Zhang J. et al. Declining Guillain–Barre syndrome after campylobacteriosis control, New Zealand, 1988–2010. Emerg Infect Dis 2012;18(2):226–33.][35. Koga M., Takahashi M., Masuda M. Campylobacter gene polymorphism as a determinant of clinical features of Guillain–Barré syndrome. Neurology 2005;65:1376–81.Koga M., Takahashi M., Masuda M. Campylobacter gene polymorphism as a determinant of clinical features of Guillain–Barré syndrome. Neurology 2005;65:1376–81.][36. Susuki K., Rasband M.N., Tohyama K. et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27(15):3956–67.Susuki K., Rasband M.N., Tohyama K. et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27(15):3956–67.][37. Yuki N., Susuki K., Koga M. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain–Barré syndrome. Proc Natl Acad Sci USA 2004;101:11404–9.Yuki N., Susuki K., Koga M. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain–Barré syndrome. Proc Natl Acad Sci USA 2004;101:11404–9.][38. Nachamkin I., Allos B.M., Ho T. Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev 1998;11(3):555–67.Nachamkin I., Allos B.M., Ho T. Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev 1998;11(3):555–67.][39. Yuki N. Guillain–Barré syndrome and anti-ganglioside antibodies: a clinicianscientist’s journey. Proc Jpn Acad Ser B Phys Biol Sci 2012;88(7):299–326.Yuki N. Guillain–Barré syndrome and anti-ganglioside antibodies: a clinicianscientist’s journey. Proc Jpn Acad Ser B Phys Biol Sci 2012;88(7):299–326.][Kuwabara S. Does Campylobacter jejuni infection elicit axonal or demyelinating Guillain–Barré syndrome, or both? J Neurol Neurosurg Psychiatry 2011;82(3):238.][40. Прудникова В.Д., Александрова В.В., Токарева Л.А. и др. Клинико-лабораторная характеристика кампилобактериоза в Липецкой области. 2005. Материалы 18-й Межрегиональной НПК «Актуальные вопросы повышения эффективности здравоохранения». Липецк, 2005.Прудникова В.Д., Александрова В.В., Токарева Л.А. и др. Клинико-лабораторная характеристика кампилобактериоза в Липецкой области. 2005. Материалы 18-й Межрегиональной НПК «Актуальные вопросы повышения эффективности здравоохранения». Липецк, 2005.]